Aztreonam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Aztreonam: From Gram-Negative Bacterial Infections to Polyclonal Hyperviscosity Syndrome
One-Sentence Summary
Aztreonam is a monobactam antibiotic that inhibits bacterial cell-wall synthesis (PBP3) and is used against gram-negative infections. The TxGNN model ranks polyclonal hyperviscosity syndrome as its top prediction, but no clinical trials and no publications support it, and the mechanism is implausible, so it is most likely a knowledge-graph artifact. Among the 10 predicted indications, gonococcal urethritis (rank 5) is the only one with meaningful clinical evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gram-negative bacterial infections (the approved indication text is not included in the record; this is based on the drug’s antibacterial class) |
| Predicted New Indication | Polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the record. Based on known information, aztreonam is a monobactam beta-lactam that inhibits penicillin-binding protein 3 (PBP3) in gram-negative bacteria. Its efficacy in bacterial infections is established.
For polyclonal hyperviscosity syndrome, the prediction is not mechanistically reasonable. The condition involves elevated serum immunoglobulins and blood viscosity. Aztreonam has no known effect on immunoglobulin levels or viscosity, and the high score is likely a knowledge-graph artifact. Several other top-ranked predictions (hyperamylasemia, congenital analbuminemia, blood group incompatibility, premalignant hematological disease) show the same problem: they are laboratory findings, genetic disorders or non-infectious conditions with no plausible antibacterial mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered for polyclonal hyperviscosity syndrome.
Literature Evidence
Currently no related literature available for polyclonal hyperviscosity syndrome.
Other Predicted Indications Worth Noting
| Rank | Predicted Indication | Score | Evidence Level | Decision | Comment |
|---|---|---|---|---|---|
| 1 | Polyclonal hyperviscosity syndrome | 99.73% | L5 | Hold | No plausible link |
| 2 | Hyperamylasemia | 99.73% | L5 | Hold | Laboratory finding, not an infection |
| 3 | Congenital analbuminemia | 99.69% | L5 | Hold | Genetic disorder |
| 4 | Ureaplasma urethritis | 99.59% | L5 | Hold | Ureaplasma has no cell wall, so beta-lactams are expected to be inactive |
| 5 | Gonococcal urethritis | 99.59% | L2 | Research Question | Direct mechanism and clinical data |
| 6 | Blood group incompatibility | 99.59% | L5 | Hold | The only retrieved paper is unrelated (plasmid genomics) |
| 7 | Premalignant hematological system disease | 99.54% | L5 | Hold | No antineoplastic activity |
| 8 | Epiglottitis | 99.53% | L4 | Hold | Plausible (H. influenzae coverage), but cephalosporins are standard |
| 9 | Monoclonal gammopathy | 99.50% | L4 | Hold | Supports treating infections in this population, not the disease itself |
| 10 | Xanthogranulomatous pyelonephritis | 99.49% | L5 | Hold | Plausible organisms, but management is surgical and no evidence was found |
Gonococcal urethritis (rank 5): the strongest candidate
Aztreonam inhibits PBP3 and has documented activity against Neisseria gonorrhoeae, including penicillin-resistant strains.
- Trial: NCT03867734 is a completed Phase 2/3 demonstration study (n=32, 2019) of aztreonam for pharyngeal gonorrhea. It appears non-randomized and does not directly show urethral efficacy.
- Recent literature: 33077658 (Antimicrob Agents Chemother, 2020) is a single-arm open-label trial of single-dose intramuscular aztreonam 2 g for N. gonorrhoeae.
- Historical clinical studies (1983–1986): Single-dose aztreonam cleared uncomplicated gonorrhea in several small studies (3157346 vs spectinomycin, no failures; 3095216, 87 patients cleared; 6438364, 30 men with urethritis).
- Resistance concern: 11406757 (2001) reported non-beta-lactamase-producing gonococci with high-level cephem and aztreonam resistance.
- Limitations: There is no randomized comparison against ceftriaxone, sample sizes are small, and aztreonam is parenteral only. The realistic niche is a reserve option for cephalosporin-resistant or beta-lactam-allergic patients.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| NDA050580 | AZACTAM | Injection, powder, for solution | A-S Medication Solutions |
| NDA050580 | AZACTAM | Injection, powder, for solution | E.R. Squibb & Sons, L.L.C. |
| ANDA206517 | Aztreonam | Injection, powder, lyophilized, for solution | Hospira, Inc. |
| NDA050580 | AZACTAM | Injection, powder, for solution | E.R. Squibb & Sons, L.L.C. |
| ANDA065439 | Aztreonam | Injection, powder, lyophilized, for solution | Fresenius Kabi USA, LLC |
All listed products are injectables. The record contains 7 authorizations in total; the 5 shown are the main entries.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, polyclonal hyperviscosity syndrome, has no clinical or literature support and no plausible mechanism, so the score reflects a knowledge-graph artifact. The only clinically supported direction is gonococcal urethritis, which is better handled as a separate research question than as this prediction.
To proceed, the following is needed:
- Drop polyclonal hyperviscosity syndrome and the other non-infectious predictions from active consideration, unless new mechanistic evidence emerges.
- For gonococcal urethritis: a randomized trial against ceftriaxone with urogenital endpoints, plus current aztreonam susceptibility data for N. gonorrhoeae.
- Package insert warnings and contraindications (blocking gap for safety screening).
- Mechanism of action data from DrugBank.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.